Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma
In advanced radioiodine-refractory DTC, PRRT may be beneficial even after treatment interruptions, without major side effects. Given the small cohort and retrospective design, further prospective studies are needed to optimize PRRT strategies in DTC, in particular in a rechallenge scenario.
Authors
- Vera Wenter (ORCID: https://orcid.org/0000-0001-7385-5702)
- Rudolf Alexander Werner (ORCID: https://orcid.org/0000-0003-3372-6046)
- Ralf Schirrmacher (ORCID: https://orcid.org/0000-0002-7098-3036)
- Adrien Holzgreve (ORCID: https://orcid.org/0000-0002-9566-8438)
- Gabriel T. Sheikh (ORCID: https://orcid.org/0000-0002-7026-9203)
- Christine Spitzweg (ORCID: https://orcid.org/0000-0002-0413-9697)
- Liam Widjaja (ORCID: https://orcid.org/0000-0002-0243-9338)
- Simon Lindner (ORCID: https://orcid.org/0009-0007-4379-4436)
- Franz Josef Gildehaus (ORCID: https://orcid.org/0000-0002-6830-1817)
- Mathias J. Zacherl
- Sophie C. Kunte (ORCID: https://orcid.org/0009-0003-3175-952X)
- Christoph J. Auernhammer
Institutions
- Johns Hopkins University (US)
- University of Alberta (CA)
- German Cancer Research Center (DE)
- Johns Hopkins Medicine (US)
- LMU Klinikum (DE)
- Bayerisches Landesamt für Umwelt (DE)
- Bavarian Broadcasting (DE)
- Mayo Clinic in Florida (US)
- Molecular Theranostics (United States) (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Molecular Imaging and Biology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1007/s11307-025-02053-w
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft